Roche Division Head Says Company Halts New Investment in Germany
A Roche division head says the Swiss pharmaceutical group is pausing new investments in Germany, citing government austerity measures, as separate reports show the company pursuing other investment and partnership activity elsewhere.
What happened
Daniel Steiners, a Roche division head, said the Swiss pharmaceutical group has suspended new investments in Germany.1
Steiners attributed the move to stringent austerity measures introduced by the German government in the healthcare sector.1
Separately, Roche figures including Oberreiter joined other industry representatives at a forum arguing that healthcare investment drives economic growth.2
Roche has also struck a deal with China's Hansoh Pharmaceutical Group to develop a portfolio of antibody-drug conjugates, continuing its pursuit of drug development partnerships in China.3
What the coverage leaves out
- None of the outlets reviewed reported the German government's response to Roche's announcement.
- None of the outlets reviewed specified which planned investments or projects in Germany are affected, or their scale.
- None of the outlets reviewed reported whether other pharmaceutical companies are taking similar action in Germany.
Why it matters
The reported suspension comes amid broader German government austerity measures in the healthcare sector, which the Roche division head cited as the reason for the pause.1
Sources (3)
Every outlet we drew on, grouped by where it is based. Read the originals for the full reporting.
North America
- 3STATUSPrivate
Russia & Eurasia
- 1TASSRUState-controlled
Swiss pharmaceutical group Roche suspends new investments in Germany, division head says
Middle East & Turkey
- 2Anadolu AgencyTRState-controlled
Roche forum highlights health care investment as driver of economic growth